Why Boston Scientific is betting $1.5B on this TAVR superalloy

In May 2026, Boston Scientific invested $1.5 billion in MiRus, the developer of the novel, balloon-expandable Siegel transcatheter aortic valve replacement (TAVR) implant featuring a proprietary molybdenum-rhenium alloy frame. Also known as MoRe, that “superalloy” (a heat-resistance, high-performanc…

View Post on Scour ↗

More from Medical Design and Outsourcing on Scour.